Stock Events

Stock Events

Zelira Therapeutics Limited 

€0.3
8
-€0-1.32% Friday 07:11

Statistics

Day High
0.3
Day Low
0.3
52W High
0.51
52W Low
0.17
Volume
0
Avg. Volume
-
Mkt Cap
3.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27AugExpected
Q4 2021
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q4 2023
Q2 2024
-0.7
-0.47
-0.23
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-358,625.05%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1,155.56Revenue
-4.14MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow G1G.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap178.43M
Corbus Pharmaceuticals focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, overlapping with Zelira's therapeutic areas.
Charlottes Web
CWBHF
Mkt Cap114.62M
Charlotte's Web Holdings produces and distributes hemp-based cannabidiol (CBD) wellness products, competing in the CBD market with Zelira.
Tilray Brands
TLRY
Mkt Cap807.33M
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, making it a direct competitor in the cannabis market.
Canopy Growth
CGC
Mkt Cap501.04M
Canopy Growth Corporation is a world-leading diversified cannabis and cannabinoid-based consumer product company, competing across multiple segments with Zelira.
Aurora Cannabis
ACB
Mkt Cap200.44M
Aurora Cannabis is involved in the production and distribution of medical cannabis, directly competing with Zelira in the medicinal cannabis market.
Cronos Group
CRON
Mkt Cap1.02B
Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents, competing with Zelira's global aspirations.

About

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Show more...
CEO
Mr. Osagie O. Imasogie Esq.
Country
Australia
ISIN
AU000000ZLD1
WKN
000A2AS5H

Listings

F
DE
G1G.F
MU
DE
G1G.MU
STU
DE
G1G.STU
AU
AU
ZLD.AU

0 Comments

Share your thoughts

FAQ

What is Zelira Therapeutics Limited stock price today?▼
The current price of G1G.F is €0.3 EUR — it has decreased by -1.32% in the past 24 hours. Watch Zelira Therapeutics Limited stock price performance more closely on the chart.
What is Zelira Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zelira Therapeutics Limited stocks are traded under the ticker G1G.F.
Is Zelira Therapeutics Limited stock price growing?▼
G1G.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Zelira Therapeutics Limited has showed a +40.19% increase.
What is Zelira Therapeutics Limited market cap?▼
Today Zelira Therapeutics Limited has the market capitalization of 3.57M
What is Zelira Therapeutics Limited revenue for the last year?▼
Zelira Therapeutics Limited revenue for the last year amounts to 1,155.56 EUR.
What is Zelira Therapeutics Limited net income for the last year?▼
G1G.F net income for the last year is -4.14M EUR.
In which sector is Zelira Therapeutics Limited located?▼
Zelira Therapeutics Limited operates in the Health & Wellness sector.
When did Zelira Therapeutics Limited complete a stock split?▼
The last stock split for Zelira Therapeutics Limited was on April 14, 2022 with a ratio of 1:175.
Where is Zelira Therapeutics Limited headquartered?▼
Zelira Therapeutics Limited is headquartered in Perth, Australia.